EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes



RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes



Diabetic Medicine 25(8): 889-894



Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. Agents that either mimic GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333951

Download citation: RISBibTeXText

PMID: 18959599

DOI: 10.1111/j.1464-5491.2008.02514.x



Related references

Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clinical Immunology 154(1): 84-89, 2014

R D Lawrence Lecture 2010. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabetic Medicine 28(2): 141-147, 2011

Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33(2): 442-449, 2010

New strategy for controlled release of drugs. Potential pinpoint targeting with multiresponsive tetraaniline diblock polymer vesicles: site-directed burst release with voltage. Acs Applied Materials & Interfaces 6(3): 1470-1480, 2015

Lawrence Lecture. The Emperor's new genes: 1993 RD Lawrence Lecture. Diabetic Medicine 11(1): 6-16, 1994

Lawrence Lecture. Hypoglycaemia and diabetes. Diabetic Medicine 3(6): 513-525, 1986

Near-infrared light activated release of nitric oxide from designed photoactive manganese nitrosyls: Strategy, design, and potential as NO donors (vol 130, pg 4447, 2008). 2007

Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review. Expert Opinion on Therapeutic Targets 16(8): 819-832, 2012

Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances. Current Drug Targets 2018, 2018

A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure. Medical Hypotheses 76(2): 234-236, 2011

RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes. Diabetic Medicine 35(1): 33-40, 2017

R.D. Lawrence Lecture 1995 Mrs Sprat's diabetes: some metabolic insights. Diabetic Medicine 13(7): 616-624, 1996

RD Lawrence lecture 2013. Stratified approaches to the management of diabetes. Diabetic Medicine 31(4): 393-398, 2014

Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. Military Medical Research 5(1): 41-41, 2018

Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy. International Journal of Cancer 143(9): 2116-2125, 2018